CD5 x TGFbR2 bispecific antibody (Xencor Inc)

N/A

Report date: 2026/01/26 17:58:56

Base Information

Drug NameCD5 x TGFbR2 bispecific antibody (Xencor Inc)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitorsTransforming growth factor beta receptor 2 inhibitors

TargetsT-cell surface glycoprotein CD5Transforming growth factor beta receptor 2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A